BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

935 related articles for article (PubMed ID: 11086492)

  • 1. [Interferon for adjuvant therapy in melanoma; although approved, not indicated].
    Groenewegen G; Osanto S; van der Rhee HJ; Punt CJ
    Ned Tijdschr Geneeskd; 2000 Nov; 144(45):2160-2. PubMed ID: 11086492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Interferon for adjuvant therapy of melanoma: approved, not indicated].
    Croockewit AJ; Koopmans PP; Lekkerkerker JF
    Ned Tijdschr Geneeskd; 2001 Mar; 145(10):498-9. PubMed ID: 11268915
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of primary and regional melanoma].
    Dreno B
    Rev Prat; 2004 Jun; 54(11):1203-9. PubMed ID: 15496027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the role of adjuvant interferon for high risk melanoma.
    Agarwala SS; Kirkwood JM
    Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
    Bajetta E
    Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
    Kirkwood JM; Tarhini AA
    Forum (Genova); 2003; 13(2):127-40; quiz 187-8. PubMed ID: 14732880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose adjuvant interferon therapy for melanoma.
    Licata AG
    Dermatol Nurs; 1998 Oct; 10(5):334-6. PubMed ID: 9873271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current management of melanoma: benefits of surgical staging and adjuvant therapy.
    McMasters KM; Swetter SM
    J Surg Oncol; 2003 Mar; 82(3):209-16. PubMed ID: 12619066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Who benefits most from adjuvant interferon treatment for melanoma?
    Gogas H; Abali H; Ascierto PA; Demidov L; Pehamberger H; Robert C; Schachter J; Eggermont AM; Hauschild A; Espinosa E
    Am J Ther; 2015; 22(1):54-60. PubMed ID: 24176884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.
    Cascinelli N; Belli F; MacKie RM; Santinami M; Bufalino R; Morabito A
    Lancet; 2001 Sep; 358(9285):866-9. PubMed ID: 11567700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.
    Agarwala SS
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1449-59. PubMed ID: 23249109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The adjuvant treatment of malignant melanoma.
    Reintgen D; Kirkwood J
    J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant melanoma and adjuvant alpha interferon-2b for patients at high risk of relapse.
    Gale DM; Kiley KE
    Clin J Oncol Nurs; 1998 Jan; 2(1):5-10. PubMed ID: 9481250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
    Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
    J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up.
    Rusciani L; Petraglia S; Alotto M; Calvieri S; Vezzoni G
    Cancer; 1997 Jun; 79(12):2354-60. PubMed ID: 9191523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current therapy of cutaneous melanoma.
    Mays SR; Nelson BR
    Cutis; 1999 May; 63(5):293-8. PubMed ID: 10349545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on PEG-interferon α-2b as adjuvant therapy in melanoma.
    Di Trolio R; Simeone E; Di Lorenzo G; Grimaldi AM; Romano A; Ayala F; Caracò C; Mozzillo N; Ascierto PA
    Anticancer Res; 2012 Sep; 32(9):3901-9. PubMed ID: 22993335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
    Kirkwood JM; Manola J; Ibrahim J; Sondak V; Ernstoff MS; Rao U;
    Clin Cancer Res; 2004 Mar; 10(5):1670-7. PubMed ID: 15014018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Melanoma: a new interferon is coming ... handle with care!].
    Négrier S
    Bull Cancer; 1997 Apr; 84(4):435-7. PubMed ID: 9238171
    [No Abstract]   [Full Text] [Related]  

  • 20. [Current therapy of carcinoma of the skin].
    Dummer R; Goldinger SM; Sailer E; French LE
    Ther Umsch; 2010 Sep; 67(9):447-52. PubMed ID: 20806173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.